Kim Ha, Chung Jinyong, Kang Jeong Wook, Schellingerhout Dawid, Lee Soo Ji, Jang Hee Jeong, Park Inyeong, Kim Taesu, Gwak Dong-Seok, Lee Ji Sung, Hong Sung-Ha, Je Kang-Hoon, Bae Hee-Joon, Sung Joohon, Lo Eng H, Faber James, Ayata Cenk, Kim Dong-Eog
Department of neurology, Dongguk University Ilsan Hospital, Goyang 10326, Republic of Korea.
National Priority Research Center for Stroke, Goyang 10326, Republic of Korea.
Theranostics. 2025 Jan 1;15(2):585-604. doi: 10.7150/thno.104132. eCollection 2025.
It remains unclear why unilateral proximal carotid artery occlusion (UCAO) causes benign oligemia in mice, yet leads to various outcomes (asymptomatic-to-death) in humans. We hypothesized that inhibition of nitric oxide synthase (NOS) both transforms UCAO-mediated oligemia into full infarction and expands pre-existing infarction. Using 900 mice, we i) investigated stroke-related effects of UCAO with/without intraperitoneal administration of the NOS inhibitor (NOSi) N-nitro-L-arginine methyl ester (L-NAME, 400 mg/kg); ii) examined the rescue effect of the NO-donor, molsidomine (200 mg/kg at 30 minutes); and iii) tested the impact of antiplatelet medications. To corroborate preclinical findings, we conducted clinical studies. UCAO alone induced infarction rarely (2%) or occasionally (14%) in C57BL/6 and BALB/c mice, respectively. However, L-NAME+UCAO induced large-arterial infarction in ~75% of C57BL/6 and BALB/c mice. Six-hour laser-speckle imaging detected spreading ischemia in ~40% of C57BL/6 and BALB/c mice with infarction (vs. none without) by 24-hours. In agreement with vasoconstriction/microthrombus formation shown by intravital-microscopy, molsidomine and the endothelial-NOS-activating antiplatelet cilostazol attenuated/prevented progression to infarction. Moreover, UCAO without L-NAME caused infarction in ~22% C57BL/6 and ~31% ApoE knock-out mice with hyperglycemia/hyperlipidemia, which associated with ~60% greater levels of symmetric dimethylarginine (SDMA, an endogenous NOSi). Further, increased levels of glucose and cholesterol associated with significantly larger infarct volumes in 438 UCAO-stroke patients. Lastly, Mendelian randomization identified a causative role of NOS inhibition (elevated SDMA concentration) in ischemic stroke risk (OR = 1.24; 95% CI, 1.11-1.38; = 7.69×10). NOS activity determines the fate of hypoperfused brain following acute UCAO, where SDMA could be a potential risk predictor.
目前尚不清楚为什么单侧近端颈动脉闭塞(UCAO)在小鼠中会导致良性低灌注,却在人类中导致各种不同的结果(从无症状到死亡)。我们假设抑制一氧化氮合酶(NOS)既能将UCAO介导的低灌注转变为完全梗死,又能扩大已有的梗死范围。我们使用了900只小鼠,进行了以下研究:i)研究腹腔注射NOS抑制剂(NOSi)N-硝基-L-精氨酸甲酯(L-NAME,400mg/kg)与否时UCAO的中风相关效应;ii)检测NO供体莫西赛利(30分钟时200mg/kg)的挽救作用;iii)测试抗血小板药物的影响。为了证实临床前研究结果,我们开展了临床研究。单独的UCAO在C57BL/6和BALB/c小鼠中分别很少(约2%)或偶尔(约14%)诱发梗死。然而,L-NAME+UCAO在约75%的C57BL/6和BALB/c小鼠中诱发大动脉梗死。6小时激光散斑成像检测到,在24小时时,约40%发生梗死的C57BL/6和BALB/c小鼠出现缺血扩展(而未发生梗死的小鼠则没有)。与活体显微镜显示的血管收缩/微血栓形成一致,莫西赛利和激活内皮型NOS的抗血小板药物西洛他唑减轻/预防了梗死进展。此外,在伴有高血糖/高血脂的C57BL/6小鼠和约31%的载脂蛋白E基因敲除小鼠中,未使用L-NAME的UCAO导致约22%的小鼠发生梗死,这与对称二甲基精氨酸(SDMA,一种内源性NOSi)水平高约60%相关。此外,在438例UCAO中风患者中,血糖和胆固醇水平升高与梗死体积显著增大相关。最后,孟德尔随机化研究确定了NOS抑制(SDMA浓度升高)在缺血性中风风险中的因果作用(比值比=1.24;95%置信区间,1.11-1.38;P=7.69×10)。NOS活性决定了急性UCAO后灌注不足的脑组织的命运,其中SDMA可能是一个潜在的风险预测指标。